AR048232A1 - Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4 - Google Patents
Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4Info
- Publication number
- AR048232A1 AR048232A1 ARP050100409A ARP050100409A AR048232A1 AR 048232 A1 AR048232 A1 AR 048232A1 AR P050100409 A ARP050100409 A AR P050100409A AR P050100409 A ARP050100409 A AR P050100409A AR 048232 A1 AR048232 A1 AR 048232A1
- Authority
- AR
- Argentina
- Prior art keywords
- groups
- alkyl
- cycloalkyl
- halogen
- och2cf3
- Prior art date
Links
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 abstract 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- -1 -C1-2 -alkylaryl Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Se refiere a su uso en medicina, a composiciones que los contienen, a procesos para su preparacion y a intermedios usados en tales procesos. Reivindicacion 1: Un compuesto de formula general (1), o una sal farmacéuticamente aceptable, hidrato, solvato, isomero o profármaco del mismo, en la que R1 se selecciona entre: grupos -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-8, -cicloalquenilo C5-8, -alquilC1-2-cicloalquiloC3-8, arilo, -alquilarilo C1-2, heterociclilo o grupos alquilC1-2-heterocíclicos; donde cada uno de los grupos R1 anteriores está opcionalmente sustituido con uno o más grupos seleccionados entre: alquilo C1-4, -(CH2)mcicloalquiloC3-5, halogeno, -(CH2)mOR6, -CN, -C(O)OR6, -(CH2)mNR7SO2R8, CF3, CH2CF3, OCF3 o OCH2CF3, donde m = 0, 1 o 2; R2 es H, OH o OCH3; R3 se selecciona entre: grupos H, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-8, -cicloalquenilo C5-8, -alquilC1-2-cicloalquiloC3-8, arilo, -alquilarilo C1-2, heterociclilo o grupos -alquilC1-2-heterocíclicos; donde cada uno de los ultimos diez grupos R3 está opcionalmente sustituido con uno o más grupos seleccionados entre: -OH, -alquilo C1-4, -(CH2)ncicloalquiloC3-5, halogeno, -CN, -(CH2)nOR6 o - (CH2)nNR7R8, donde n = 0, 1 o 2; R4 se selecciona entre: -H, -alquilo C1-4, -alquenilo C2-4, -alquinilo C2-4, -(CH2)pcicloalquiloC3-5, -(CH2)pciclo-alqueniloC5, halogeno, -(CH2)pOR6, (CH2)pNR7R8, -CN, -C(O)R6, -C(O)OR6, -C(O)NR7R8, -(CH2)pNR7SO2R8, CF3, CH2CF3, OCF3 o OCH2CF3, donde p = 0, 1 o 2; R5 se selecciona entre: grupos -alquilo C1-4, -alquenilo C2-4, -alquinilo C2-4, -(CH2)pcicloalquiloC3-5, -(CH2)pciclo-alqueniloC5, halogeno, -(CH2)pOR6, (CH2)pNR7R8, -CN, -C(O)R6, -C(O)OR6, - C(O)NR7R8, -(CH2)pNR7SO2R8, CF3, CH2CF3, OCF3 o OCH2CF3, donde p = 0, 1 o 2; o R4 y R5 pueden formar conjuntamente u anillo saturado o insaturado de 5 a 7 miembros condensado; cada uno de R6, R7 y R8 se selecciona independientemente entre H, CH3 o CH2CH3; y donde los grupos heterocíclicos de R1 y R3 se seleccionan independientemente entre sistemas de anillo de 4 a 10 miembros que contienen hasta 4 heteroátomos seleccionados independientemente entre O, N o S.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402492.3A GB0402492D0 (en) | 2004-02-04 | 2004-02-04 | Pharmaceutically active compounds |
| GB0412417A GB0412417D0 (en) | 2004-06-03 | 2004-06-03 | Pharmaceutically active compounds |
| GB0425530A GB0425530D0 (en) | 2004-11-19 | 2004-11-19 | Pharmaceutically active compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048232A1 true AR048232A1 (es) | 2006-04-12 |
Family
ID=34864830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100409A AR048232A1 (es) | 2004-02-04 | 2005-02-03 | Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1716135B1 (es) |
| JP (1) | JP4031814B2 (es) |
| KR (1) | KR100830763B1 (es) |
| CN (1) | CN1930146A (es) |
| AP (1) | AP2006003699A0 (es) |
| AR (1) | AR048232A1 (es) |
| AT (1) | ATE511507T1 (es) |
| AU (1) | AU2005213538A1 (es) |
| BR (1) | BRPI0507435A (es) |
| CA (1) | CA2555800C (es) |
| CR (1) | CR8545A (es) |
| EA (1) | EA011159B1 (es) |
| EC (1) | ECSP066751A (es) |
| GB (1) | GB0402492D0 (es) |
| GE (1) | GEP20084361B (es) |
| IL (1) | IL177004A0 (es) |
| MA (1) | MA28348A1 (es) |
| NL (1) | NL1028193C2 (es) |
| NO (1) | NO20063944L (es) |
| PA (1) | PA8623101A1 (es) |
| PE (1) | PE20050772A1 (es) |
| TW (1) | TWI300066B (es) |
| UY (1) | UY28737A1 (es) |
| WO (1) | WO2005077935A1 (es) |
| ZA (1) | ZA200606236B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007015162A1 (en) * | 2005-08-04 | 2007-02-08 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
| KR20080048502A (ko) * | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| US7652024B2 (en) * | 2005-10-18 | 2010-01-26 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| CN101426782B (zh) * | 2006-02-23 | 2012-10-31 | 辉瑞股份有限公司 | 黑皮质素4型受体激动剂哌啶羰基吡咯烷 |
| AP2008004602A0 (en) * | 2006-02-23 | 2008-10-31 | Pfizer Ltd | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
| AU2008284662B2 (en) | 2007-08-07 | 2013-07-25 | Takeda Pharmaceutical Company Limited | Pyrrolidin-2 -one derivatives as androgen receptor modulator |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| MY193597A (en) * | 2014-05-29 | 2022-10-19 | Mitsubishi Tanabe Pharma Corp | Novel pyrrolidine compound and application as melanocortin receptor agonist |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| PT3333165T (pt) * | 2015-08-04 | 2019-10-29 | Astellas Pharma Inc | Derivado de piperazina |
| CN112694436B (zh) * | 2020-12-30 | 2022-07-08 | 济南周行医药科技有限公司 | 一种槟榔碱的合成方法 |
| CA3217201A1 (en) * | 2021-05-06 | 2022-11-10 | Lg Chem, Ltd. | Crystal form vii of melanocortin receptor agonist compound and method for preparing same |
| CN114211258B (zh) * | 2021-11-04 | 2023-09-26 | 江阴市大久金属科技有限公司 | 高精密无缝钢管制备工艺 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20053710B (en) * | 2001-02-28 | 2005-12-26 | Merck & Co Inc | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists |
| EP1372653B1 (en) * | 2001-02-28 | 2006-10-04 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
-
2004
- 2004-02-04 GB GBGB0402492.3A patent/GB0402492D0/en not_active Ceased
-
2005
- 2005-01-26 CA CA2555800A patent/CA2555800C/en not_active Expired - Fee Related
- 2005-01-26 JP JP2006551945A patent/JP4031814B2/ja not_active Expired - Fee Related
- 2005-01-26 WO PCT/IB2005/000208 patent/WO2005077935A1/en not_active Ceased
- 2005-01-26 AP AP2006003699A patent/AP2006003699A0/xx unknown
- 2005-01-26 BR BRPI0507435-5A patent/BRPI0507435A/pt not_active IP Right Cessation
- 2005-01-26 EA EA200601279A patent/EA011159B1/ru not_active IP Right Cessation
- 2005-01-26 AU AU2005213538A patent/AU2005213538A1/en not_active Abandoned
- 2005-01-26 GE GEAP20059564A patent/GEP20084361B/en unknown
- 2005-01-26 KR KR1020067015811A patent/KR100830763B1/ko not_active Expired - Fee Related
- 2005-01-26 AT AT05702363T patent/ATE511507T1/de not_active IP Right Cessation
- 2005-01-26 CN CNA2005800075736A patent/CN1930146A/zh active Pending
- 2005-01-26 EP EP05702363A patent/EP1716135B1/en not_active Expired - Lifetime
- 2005-02-02 PE PE2005000122A patent/PE20050772A1/es not_active Application Discontinuation
- 2005-02-03 TW TW094103372A patent/TWI300066B/zh active
- 2005-02-03 AR ARP050100409A patent/AR048232A1/es not_active Application Discontinuation
- 2005-02-03 UY UY28737A patent/UY28737A1/es not_active Application Discontinuation
- 2005-02-04 NL NL1028193A patent/NL1028193C2/nl not_active IP Right Cessation
- 2005-02-04 PA PA20058623101A patent/PA8623101A1/es unknown
-
2006
- 2006-07-20 IL IL177004A patent/IL177004A0/en unknown
- 2006-07-27 ZA ZA200606236A patent/ZA200606236B/xx unknown
- 2006-08-03 EC EC2006006751A patent/ECSP066751A/es unknown
- 2006-08-03 CR CR8545A patent/CR8545A/es not_active Application Discontinuation
- 2006-08-04 MA MA29242A patent/MA28348A1/fr unknown
- 2006-09-04 NO NO20063944A patent/NO20063944L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005213538A1 (en) | 2005-08-25 |
| JP4031814B2 (ja) | 2008-01-09 |
| CR8545A (es) | 2007-09-03 |
| GEP20084361B (en) | 2008-04-29 |
| CA2555800A1 (en) | 2005-08-25 |
| ATE511507T1 (de) | 2011-06-15 |
| ECSP066751A (es) | 2006-11-16 |
| MA28348A1 (fr) | 2006-12-01 |
| EA200601279A1 (ru) | 2006-12-29 |
| UY28737A1 (es) | 2005-09-30 |
| GB0402492D0 (en) | 2004-03-10 |
| ZA200606236B (en) | 2008-04-30 |
| NO20063944L (no) | 2006-10-31 |
| BRPI0507435A (pt) | 2007-07-03 |
| AP2006003699A0 (en) | 2006-08-31 |
| EP1716135B1 (en) | 2011-06-01 |
| PE20050772A1 (es) | 2005-10-31 |
| TWI300066B (en) | 2008-08-21 |
| TW200526625A (en) | 2005-08-16 |
| KR100830763B1 (ko) | 2008-05-19 |
| EP1716135A1 (en) | 2006-11-02 |
| WO2005077935A1 (en) | 2005-08-25 |
| NL1028193C2 (nl) | 2006-04-20 |
| PA8623101A1 (es) | 2006-05-16 |
| CA2555800C (en) | 2010-06-15 |
| JP2007534668A (ja) | 2007-11-29 |
| NL1028193A1 (nl) | 2005-08-08 |
| CN1930146A (zh) | 2007-03-14 |
| IL177004A0 (en) | 2006-12-10 |
| EA011159B1 (ru) | 2009-02-27 |
| KR20060127125A (ko) | 2006-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
| PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
| AR051997A1 (es) | Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR030243A1 (es) | Carboxamidas heterociclicas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento antiviral y metodo in vitro para inhibir el adn polimerasa viral | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| AR069309A1 (es) | Derivados de imidazo[1,2-a] piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos. | |
| RU2013151803A (ru) | Бициклические гетероциклические соединения и их применения в терапии | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR058703A1 (es) | Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer | |
| AR040474A1 (es) | Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR057712A1 (es) | Dihidropteridinonas en el tratamiento de enfermedades respiratorias | |
| CL2008002132A1 (es) | Compuestos derivados de sulfonamidas, moduladores de trpm8; composiciones farmaceuticas que comprenden a dichos compuestos; y uso de dichos compuestos en el tratamiento del dolor neuropatico, dolor inflamatorio, ansiedad, depresion, hiperalgesia inflamatoria, entre otras. | |
| AR068045A1 (es) | Derivados de catecolamina y prodrogas de los mismos | |
| AR074352A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica. | |
| CO2017008809A2 (es) | Compuestos de benzoxaborol y uso de los mismos | |
| AR038213A1 (es) | Esteres hidroxamato del acido n-(4-fenil sustituido)-antranilico | |
| AR046942A1 (es) | Arilpirazoles sustituidos, un procedimiento para su preparacion, composiciones farmaceuticas o veterinarias que los contienen como principio activo y su uso en la fabricacion de un medicamento parasiticida humano o animal. | |
| AR100073A1 (es) | Sulfonas heterocíclicas sustituidas con heteroarilos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |